相关实验视频

Updated: Jan 11, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

骨髓瘤免疫代谢:新出现的机制和临床影响

Bowen Tan¹, Jingyuan Ning²

¹Fifth Department of Orthopaedics, The Third Affiliated Hospital of Qiqihar Medical College, Qiqihar, China.

Frontiers in immunology

|November 10, 2025

概括

骨髓瘤 (OS) 细胞重编程新陈代谢,创造一个免疫抑制瘤微环境 (TME),限制免疫疗法的有效性. 针对这些代谢途径为新型OS癌症治疗提供了一个有希望的战略.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
代谢研究研究代谢研究

背景情况:

骨髓瘤 (OS) 是一种常见于青少年和年轻成年人的原发性骨癌.
目前的治疗方法对转移性或复发性OS的存活率很低,需要新的治疗方法.
由于受损的免疫代谢交叉交互,OS经常抵抗免疫疗法.

研究的目的:

分析目前对骨髓瘤免疫代谢的理解.
确定阻碍OS有效免疫治疗的代谢障碍.
提出开发有针对性的生物标志物驱动疗法的路线图.

主要方法:

对有关OS免疫代谢的现有文献进行系统审查和批判性分析.
从一般概念来界定OS特定的代谢重编程.
检查瘤微环境 (TME) 内的代谢变化.

主要成果:

运行系统细胞表现出独特的代谢重编程以支持快速生长.
在OS中发生的代谢变化会产生免疫抑制的TME,损害免疫细胞功能.
失调的免疫代谢是OS免疫疗法耐药性的关键因素.

结论:

准OS中的免疫代谢途径是一个可行的策略,以提高免疫治疗的疗效.
了解OS特异性新陈代谢对于克服治疗耐药性至关重要.
需要基于生物标志物的方法来开发更有效的OS治疗方法.

关键词:

免疫代谢的免疫代谢.免疫疗法免疫疗法代谢重编程是指代谢重编程.骨质肉瘤是骨质肉瘤的一种疾病.瘤微环境是一个微环境.

更多相关视频

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...